Insellar is developing a new class of brain interfaces that work with the body’s own systems to improve mental health. The company focuses on minimally invasive, physiological approaches to treating major depressive disorder and ‘beyond.’ Its stated approach emphasizes working with natural body processes rather than relying on more general or non-specific stimulation.
On its website and in its company profile, Insellar says it welcomes contact from collaborators, investors, clinicians, and patients who want to advance this vision together. The company is headquartered in Berlin and is described on LinkedIn as a privately held biotechnology research organization. Founded in 2025, Insellar currently lists a very small team size (2–10 employees on LinkedIn) and presents its work as inner brain interface and neurotech research aimed at new therapeutic options.
